Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shawn Puri

Interventional Pain Medicine Killeen, TX Medical Doctor

NPI 1598056293 CMS profile 1387286

3800 S W S Young Dr Ste 201, Killeen, TX 76542

Open in the dashboard

General payments

$36,800

735 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shawn Puri of Killeen, TX is reported in the CMS Open Payments database as having received $36,800 across 735 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,237 73
2024 General $2,843 77
2023 General $11,146 224
2022 General $10,026 97
2021 General $2,951 43
2020 General $2,160 34
2019 General $5,437 187

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shawn Puri
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Shawn Puri were reported at $2,237. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Shawn Puri Interventional Pain Medicine median Middle half National median
2019 $5,437 $684 $216–$2,079 $163
2020 $2,160 $382 $122–$1,109 $114
2021 $2,951 $552 $167–$1,554 $132
2022 $10,026 $605 $187–$1,924 $149
2023 $11,146 $671 $195–$1,915 $160
2024 $2,843 $684 $206–$1,837 $164
2025 $2,237 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $14,004 391 payments
  2. Vertos Medical, Inc. $5,694 17 payments
  3. Omnia Medical, LLC $4,500 2 payments
  4. Nevro Corp. $2,457 45 payments
  5. SPR Therapeutics, Inc $1,541 21 payments
  6. Spinal Simplicity, LLC $1,340 40 payments
  7. Medtronic, Inc. $1,180 17 payments
  8. Vertiflex, Inc. $1,167 9 payments
  9. Boston Scientific Corporation $971 52 payments
  10. Relievant Medsystems, Inc. $750 9 payments
  11. Other $3,198 132 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $23,588 710 payments
  2. Consulting Fee $9,900 5 payments
  3. Travel and Lodging $3,200 16 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $84 2 payments
  5. Education $18 1 payment
  6. Gift $10 1 payment
Products named General payments · program years 2019–2025
  1. mild Device Kit $4,967 8 payments
  2. PROCLAIM Neuromodulation $3,809 111 payments
  3. PROCLAIM Neuromodulation $2,338 40 payments
  4. OCTRODE $2,251 54 payments
  5. SPRINT PNS System $1,541 21 payments
  6. HA MINUTEMAN G3-R $1,340 40 payments
  7. PROCLAIM Neuromodulation $1,270 19 payments
  8. Superion ISS $1,167 9 payments
  9. Senza $1,071 16 payments
  10. Proclaim Family of SCS IPGs $1,017 43 payments
  11. Other $14,032 433 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

2,498

Median for Pain Management: 951

Drug cost

$105,788

Median for Pain Management: $26,034

Branded share of claims

50%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belbuca Buprenorphine Hcl Brand 61 $44,755
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 783 $17,947
Xtampza Er Oxycodone Myristate Brand 22 $9,392
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 246 $6,125
Linzess Linaclotide Brand 11 $5,319
Buprenorphine Generic 17 $3,179
Lidocaine Generic 36 $3,178
Gabapentin Generic 223 $2,820
Pregabalin Generic 119 $2,458
Tramadol Hcl Er Tramadol Hcl Brand 22 $1,493

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$170,930

Of which drugs: $3,459

Medicare patients

511

Average age 70

Services billed

3,190

311 women, 200 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 39%
Depression 30%
Ischemic heart disease 27%
Chronic kidney disease 22%
COPD 17%
Heart failure 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 28 300 $26

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

735 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record